Skin Disorders News

CLEVELAND — Patients with rosacea, livedoid vasculopathy and allergic contact dermatitis present with a multitude of dermatologic symptoms that rheumatologists can easily misdiagnose as rheumatic diseases, according to Anthony Fernandez, MD, PhD, of the Cleveland Clinic.

A Danish cohort study revealed that nearly one-in-four patients with inflammatory bowel disease have another immune mediated inflammatory disease which can impact disease course and increase severity.

Supplementing atopic dermatitis treatment with probiotics does not benefit children, according to research presented at the American Academy of Allergy, Asthma and Immunology annual meeting.

Faced with an increasing incidence and prevalence of autoimmune disease in the United States —approximately 23.5 million Americans are affected across the country, according to the NIH — Bonnie Feldman, MBA, DDS, says it is time to acknowledge what she calls “an invisible epidemic.”

Regeneron Pharmaceuticals and Sanofi announced that the FDA has approved Dupixent for patients aged 12 to 17 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled by topical prescriptions or when those therapies are not advisable.

Although children with and without atopic dermatitis receive a comparable amount of sleep, children with the condition are more likely to have a reduced quality of sleep, regardless of the severity of disease.

Mothers who exclusively breastfed for longer than 3 months significantly lowered their child’s risk of eczema, according to findings presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting.

Subcutaneous lanadelumab, a monoclonal antibody drug, for 26 weeks significantly reduces attack rates of hereditary angioedema, according to data published in JAMA.

The skin of children with early-onset atopic dermatitis exhibits significantly different phenotypes when compared with the skin of adults with a long-standing history with the disease, according to research published in The Journal of Allergy and Clinical Immunology.

BOSTON — Advances in the understanding of epigenetic modifications — changes in gene activity without changes in DNA sequencing — could lead to the development of new biomarkers and potential therapies for immune-modulated inflammatory diseases, according to a presentation given at the Interdisciplinary Autoimmune Summit.